Pulmonx Corporation (NASDAQ:LUNG) Receives $5.58 Consensus Price Target from Brokerages

Pulmonx Corporation (NASDAQ:LUNG) has been assigned an average rating of “Hold” from the seven research firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $5.5833.

A number of research analysts recently weighed in on the stock. D. Boral Capital reissued a “buy” rating and issued a $14.00 target price on shares of Pulmonx in a report on Thursday, April 30th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pulmonx in a research note on Monday, July 13th. Finally, Wall Street Zen upgraded shares of Pulmonx from a “sell” rating to a “hold” rating in a research report on Saturday, June 27th.

Pulmonx Stock Performance

NASDAQ LUNG opened at $1.35 on Thursday. The stock has a market capitalization of $57.24 million, a PE ratio of -1.04 and a beta of 0.30. The business has a 50 day simple moving average of $1.43 and a two-hundred day simple moving average of $1.52. The company has a debt-to-equity ratio of 0.81, a current ratio of 4.91 and a quick ratio of 4.04. Pulmonx has a 1-year low of $1.13 and a 1-year high of $3.88.

Pulmonx (NASDAQ:LUNG) last released its quarterly earnings data on Wednesday, April 29th. The company reported ($0.33) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.33). The business had revenue of $20.59 million for the quarter, compared to the consensus estimate of $20.43 million. Pulmonx had a negative return on equity of 92.94% and a negative net margin of 60.09%. On average, research analysts predict that Pulmonx will post -1.13 EPS for the current fiscal year.

Institutional Trading of Pulmonx

Several hedge funds have recently made changes to their positions in LUNG. R Squared Ltd purchased a new position in Pulmonx in the first quarter worth about $26,000. Cerity Partners LLC purchased a new stake in Pulmonx during the fourth quarter valued at approximately $27,000. FNY Investment Advisers LLC bought a new stake in shares of Pulmonx in the 3rd quarter valued at approximately $29,000. Opal Capital LLC bought a new stake in shares of Pulmonx in the 4th quarter valued at approximately $29,000. Finally, Regatta Capital Group LLC purchased a new position in shares of Pulmonx in the 4th quarter worth approximately $30,000. 91.04% of the stock is currently owned by hedge funds and other institutional investors.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.